High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant-Reference-Cited by-同舟云学术

High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant

Published:2015-01-26 Issue:4 Volume:50 Page:499-504
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Castagna L,Crocchiolo R,Giordano L,Bramanti S,Carlo-Stella C,Sarina B,Chiti A,Mauro E,Gandolfi S,Todisco E,Balzarotti M,Anastasia A,Magagnoli M,Brusamolino E,Santoro A

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2014304.pdf

Reference35 articles.

1. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071.

2. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297.

3. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 27: 4184–4190.

4. Ardeshna KM, Kakouros N, Qian W, Powell MG, Saini N, D'Sa S et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol 2005; 130: 363–372.

5. Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012; 119: 1665–1670.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT;Bone Marrow Transplantation;2020-10-12

2. Hyperhydration is not necessary for high-dose melphalan in stem cell transplantation;Bone Marrow Transplantation;2019-06-11

3. Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703);Biology of Blood and Marrow Transplantation;2018-04

4. Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma;Bone Marrow Transplantation;2017-12-21

5. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study;Journal of Clinical Oncology;2016-09-20